Barnaby Hunt (B Hunt)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 37

Top Topics

Glycemic Control

Patients With Inflammatory Bowel Disease

Ulcerative Colitis

Top Venues

Journal of medical economics

Diabetes, obesity & metabolism

Diabetes therapy : research, treatment and education of diabetes and related disorders

Advances in therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Antonio Ramirez de Arellano, Gabrielius Jakutis, Barnaby Hunt
Cost analysis of patiromer vs sodium zirconium cyclosilicate for the treatment of hyperkalemia in Spain and the UK. Journal of medical economics 27 (1) (2024)
Antonio Ramirez de Arellano, Gabrielius Jakutis, Barnaby Hunt
Cost analysis of patiromer versus sodium zirconium cyclosilicate for the treatment of hyperkalemia in Spain and the UK. Journal of medical economics (2024)
Robert Gerald Jan Moes, Eline L Huisman, Samuel J P Malkin, Barnaby Hunt
Evaluating the Clinical and Economic Outcomes Associated with Poor Glycemic Control in People with Type 1 Diabetes in the Netherlands. ClinicoEconomics and outcomes research : CEOR 15 (2023)
Robert Gerald Jan Moes, Eline L Huisman, Samuel J P Malkin, Barnaby Hunt
Evaluating the Clinical and Economic Outcomes Associated with Poor Glycemic Control in People with Type 1 Diabetes in the Netherlands. ClinicoEconomics and outcomes research : CEOR 15 (2023)
Jean-François Yale, Beatrice Osumili, Beth D Mitchell, Barnaby Hunt, Gurjeev Sohi, Mark Jeddi, Donna Mojdami, William J Valentine
Evaluation of the cost and medical resource use outcomes associated with nasal glucagon versus injectable glucagon for treatment of severe hypoglycemia in people with diabetes in Canada: a modeling analysis. Journal of medical economics 25 (1) (2022)
Lyndon Marc Evans, Sasha Berry, Avideh Nazeri, Samuel Joseph Paul Malkin, Donna Ashley, Barnaby Hunt, Stephen C Bain
The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes. Diabetes, obesity & metabolism (2022)
Federico Argüelles-Arias, Fernando Bermejo, Joaquín Borrás-Blasco, Eugeni Domènech, Beatriz Sicilia, José M Huguet, Antonio Ramirez de Arellano, William J Valentine, Barnaby Hunt
Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain. Therapeutic advances in gastroenterology 15 (2022)
Lyndon Marc Evans, Barrie Chubb, Samuel Joseph Paul Malkin, Sasha Berry, Jack Lawson, Barnaby Hunt
Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11. Diabetes, obesity & metabolism (2022)
Matthew Capehorn, Nino Hallén, James Baker-Knight, Divina Glah, Barnaby Hunt
Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting. Diabetes therapy : research, treatment and education of diabetes and related disorders 12 (2) (2021)
Aysegül Aksan, Ian L P Beales, Garth Baxter, Antonio Ramirez de Arellano, Simona Gavata, William J Valentine, Barnaby Hunt
Evaluation of the Cost-Effectiveness of Iron Formulations for the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease in the UK. ClinicoEconomics and outcomes research : CEOR 13 (2021)
Johan H Jendle, Åsa Ericsson, Bertil Ekman, Stefan Sjöberg, Jens Gundgaard, João da Rocha Fernandes, Ann-Charlotte Mårdby, Barnaby Hunt, Samuel Joseph Paul Malkin, Maria Thunander
Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective. Journal of medical economics 23 (11) (2020)
Virginia Martín, Josep Vidal, Samuel J P Malkin, Nino Hallén, Barnaby Hunt
Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting. Advances in therapy 37 (10) (2020)
Aysegül Aksan, Alain Schoepfer, Pascal Juillerat, Stephan Vavricka, Miguel Bettencourt, Antonio Ramirez de Arellano, Simona Gavata, Neige Morin, William J Valentine, Barnaby Hunt
Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland. Advances in therapy 38 (1) (2020)
Ataru Igarashi, Barnaby Hunt, Lars Wilkinson, Jakob Langer, Richard F Pollock
Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis. Advances in therapy 37 (10) (2020)
B B Hansen, Solomon Nuhoho, S N Ali, T Dang-Tan, W J Valentine, S J P Malkin, Barnaby Hunt
Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis. Journal of medical economics 23 (6) (2020)
Josep Vidal, Samuel J P Malkin, Barnaby Hunt, Virginia Martín, Nino Hallén, Francisco Javier Ortega
The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain. Diabetes therapy : research, treatment and education of diabetes and related disorders 11 (2) (2020)
Juan José Gorgojo-Martínez, Samuel J P Malkin, Virginia Martín, Nino Hallén, Barnaby Hunt
Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin. Journal of medical economics 23 (2) (2019)
Barnaby Hunt, Brian B Hansen, Åsa Ericsson, Klaus Kallenbach, Sarah N Ali, Tam Dang-Tan, Samuel J P Malkin, William J Valentine
Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States. Advances in therapy 36 (12) (2019)
Pierre Johansen, Barnaby Hunt, Neeraj N Iyer, Tam Dang-Tan, Richard F Pollock
A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA. Advances in therapy 36 (5) (2019)
Barnaby Hunt, Samuel J P Malkin, Robert G J Moes, Eline L Huisman, Tom Vandebrouck, Bruce H R Wolffenbuttel
Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands. BMJ open diabetes research & care 7 (1) (2019)
Stephen C Bain, Brian B Hansen, Samuel J P Malkin, Solomon Nuhoho, William J Valentine, Barrie Chubb, Barnaby Hunt, Matthew Capehorn
Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme. Diabetes therapy : research, treatment and education of diabetes and related disorders 11 (1) (2019)
Pedro Mezquita Raya, Francisco Javier Ampudia Blasco, Barnaby Hunt, Virginia Martin, Brian Larsen Thorsted, Amaury Basse, Hermione C Price
Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence. Diabetes, obesity & metabolism 21 (6) (2019)
Johannes Pöhlmann, Monika Russel-Szymczyk, Pavel Holík, Karel Rychna, Barnaby Hunt
Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi. Diabetes therapy : research, treatment and education of diabetes and related disorders 10 (2) (2019)
Johannes Pöhlmann, Roberta Montagnoli, Giusi Lastoria, Witesh Parekh, Marie Markert, Barnaby Hunt
Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy. ClinicoEconomics and outcomes research : CEOR 11 (2019)
Samuel J P Malkin, Monika Russel-Szymczyk, Marek Psota, Lucia Hlavinkova, Barnaby Hunt
The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia. Advances in therapy 36 (8) (2019)
Stephen C Bain, Brian Bekker Hansen, Barnaby Hunt, Barrie Chubb, William J Valentine
Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK. Journal of medical economics 23 (1) (2019)
Russell Drummond, Samuel Joseph Paul Malkin, Michelle Du Preez, Xin Ying Lee, Barnaby Hunt
The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting. Diabetes, obesity & metabolism 20 (10) (2018)
Anthony H Barnett, Simon Arnoldini, Barnaby Hunt, Gowri Subramanian, Christina Stentoft Hoxer
Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis. Diabetes, obesity & metabolism 20 (8) (2018)
Samuel J P Malkin, Monika Russel-Szymczyk, Girtel Liidemann, Vallo Volke, Barnaby Hunt
Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia. Diabetes therapy : research, treatment and education of diabetes and related disorders 10 (1) (2018)
Michael Dempsey, Michelle Mocarski, Jakob Langer, Barnaby Hunt
Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US. Journal of medical economics 21 (11) (2018)
Adie Viljoen, Christina S Hoxer, Pierre Johansen, Samuel Joseph Paul Malkin, Barnaby Hunt, Stephen C Bain
Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. Diabetes, obesity & metabolism 21 (3) (2018)
David Russell-Jones, Simon R Heller, Sarah Buchs, Anna Sandberg, William J Valentine, Barnaby Hunt
Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting. Diabetes, obesity & metabolism 19 (12) (2017)
Barnaby Hunt, C C McConnachie, C Gamble, T Dang-Tan
Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States. Journal of medical economics 20 (11) (2017)
Barnaby Hunt, Michelle Mocarski, William J Valentine, Jakob Langer
IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting. Diabetes therapy : research, treatment and education of diabetes and related disorders 8 (3) (2017)
Pedro Mezquita-Raya, Antonio Ramírez de Arellano, Nana Kragh, Gabriela Vega-Hernandez, Johannes Pöhlmann, William J Valentine, Barnaby Hunt
Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain. Diabetes therapy : research, treatment and education of diabetes and related disorders 8 (2) (2017)
Barnaby Hunt, Gabriela Vega-Hernandez, William J Valentine, Nana Kragh
Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting. Diabetes, obesity & metabolism 19 (6) (2017)
Barnaby Hunt, Michelle Mocarski, William J Valentine, Jakob Langer
Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA. Advances in therapy 34 (4) (2017)